Clinical trial
A Prospective, Randomized, Double-blind Crossover Study Comparing 0.15 g/L rhBSSL Added to Pasteurized Breast Milk Versus Placebo During One Week of Treatment in Preterm Infants Born Before Week 32 of Gestational Age
NCT00659243 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Double-blind Crossover Study Comparing 0.15 g/L rhBSSL Added to Pasteurized Breast Milk Versus Placebo During One Week of Treatment in Preterm Infants Born Before Week 32 of Gestational Age
- Lead sponsor
- Swedish Orphan Biovitrum
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2008
- Completion date
- February 28, 2010
- Enrollment
- 32 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
replacement therapy in preterm infants